articleTop 1% cited

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

JNCI Journal of the National Cancer Institute · 1993 · Vol. 85(5) · pp. 365–376

N.K. Aaronson✉(The Netherlands Cancer Institute)Sam H. AhmedzaiBengt BergmanMonika Bullinger(Zimmer Biomet (Germany))A. CullN. Duez(European Organisation for Research and Treatment of Cancer)A. Filiberti(Fondazione IRCCS Istituto Nazionale dei Tumori)Hans‐Henning Flechtner(University of Cologne)Stewart B. Fleishman(Long Island Jewish Medical Center)J.C.J.M. de Haes(University of Amsterdam)S. Kaasa(Norwegian Cancer Society)M. Klee(Rigshospitalet)David Osoba(BC Cancer Agency)Darius Razavi(Institut Jules Bordet)Peter B. C. Rofe(Royal Adelaide Hospital)S Schraub(Centre Hospitalier Universitaire de Besançon)K.C.A. Sneeuw(The Netherlands Cancer Institute)Marianne Sullivan(Sahlgrenska University Hospital)Fumikazu Takeda(Saitama Cancer Center)

View via DOI Publisher page

Abstract

These results support the EORTC QLQ-C30 as a reliable and valid measure of the quality of life of cancer patients in multicultural clinical research settings. Work is ongoing to examine the performance of the questionnaire among more heterogenous patient samples and in phase II and phase III clinical trials.

Cancer survivorship and care Head and Neck Cancer Studies Lung Cancer Treatments and MutationsQuality of life (healthcare)Cronbach's alphaClinical trialConstruct validityMedicineNauseaPhysical therapyReliability (semiconductor)PsychologyPsychometrics

MeSH terms

Activities of Daily LivingAdultAgedAged, 80 and overClinical Trials as TopicFemaleHealth StatusHumansLung NeoplasmsMaleMiddle AgedQuality of LifeSurveys and QuestionnairesReproducibility of Results

Citations

15,705

FWCI

27.62

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer